[Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003548:Cysteinyldopa / Q000031:analogs & derivatives / Q000652:urine*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000628:therapy* / Q000652:urine; D008875:Middle Aged; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D015376:Nimustine; D003548:Cysteinyldopa; C033574:glutathionyldopa; D014750:Vincristine; D004295:Dihydroxyphenylalanine; C027168:5-(3,3-dimethyl-1-triazeno)-1-methylimidazole-4-carboxamide; D003606:Dacarbazine